Tag Archives: hydroxychloroquine

The Key to Defeating COVID-19 Already Exists. We Need to Start Using It – HARVEY A. RISCH, MD, PHD

Publication references from the video:
Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis
https://bit.ly/2BBs21K
The Key to Defeating COVID-19 Already Exists. We Need to Start Using It
https://bit.ly/2EeZdZM
Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows
https://bit.ly/3hQAjhV
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
https://bit.ly/2P20JR2

***

FRONTLINE DOCTORS SPEAK OUT ON COVID CURES AND MISINFORMATION

YouTube is taking down this video left and right

Frontline Doctors Speak Out ON COVID Cures and Misinformation

“The dose, my friends, is 200 milligrams [HCQ] twice in a week, and zinc daily. That’s the dose. I’m in favor of it being over-the-counter; give it to the people.”

– Doctor on HCQ as a simple prophylaxis

(25:21 to around 30 minutes for discussion on this treatment by three doctors) https://banned.video/watch?id=5f1fc7a468370e02f29f34cf

TWITTER FAKE NEWS CENSORSHIP OF HYDROXYCHLORIQUINE (720)

Why Isn’t Hydroxychloroquine Available Over The Counter?

It is time to take the bull by the horns to conquer the Wuhan virus. Drastic action is necessary, like on December 8, 1941 after Japan bombed Pearl Harbor.

President Trump should order immediate public access to hydroxychloroquine (HCQ) by making the medication available over-the-counter (OTC). Liberals have interfered with public access to this medication for COVID-19 through the old-fashioned route of requiring a prescription and then having a pharmacist fill or reject the prescription.

Millions of Americans do not visit physicians, and cannot obtain a prescription for HCQ if they did. Even if you have been exposed to COVID-19, you cannot obtain a prescription for HCQ in most states because regulators prohibit dispensing it without a positive test result, which typically cannot be obtained until late in the progression of the disease.

No one credibly doubts that HCQ is safe, and safer than many medications currently available OTC. No one credibly doubts the dozens of studies showing that early use of HCQ, pre-exposure and immediately after exposure to COVID, has helped many overcome this dreaded disease.

Americans do not need a prescription to obtain hundreds of medications which once required a prescription. Nexium, Prevacid, Prilosec, Claritin, Flonase, and Primatene Mist are medications that have been shifted from Rx to OTC in recent years, not because the medical establishment pushed for the change, but because of public demand for it.

No demand is higher at this time than for a medication which helps prevent against COVID. Yet Americans are not being allowed to access the medication which they want and need, and instead are being told by FDA and state officials that they cannot have it.

Last month the Oregon pharmacy board, for example, blocked HCQ access as follows:

“Prescription orders for chloroquine or hydroxychloroquine for the prevention or treatment of COVID-19 infection may only be dispensed if written for a patient enrolled in a clinical trial by an authorized investigator.”

They based their ban on an improper statement issued by FDA, which is controlled by opponents of Trump’s reelection. Of course, many government officials in Oregon are against Trump, too.

Every state board of pharmacy or medicine is controlled by left-leaning government workers who, by and large, despise President Trump and hope he loses in November. They are accomplishing their dream by choking off public access to HCQ.

In other countries, such as Costa Rica and Honduras, HCQ is being given freely to the public to successfully defeat coronavirus there. In some countries officials are even going door-to-door distributing HCQ to build up protection against the virus, with great success.

The mortality rate from COVID-19 in the United States is far higher per case, and per million of residents, despite how we have the finest hospital system in the world. We don’t currently have public access to HCQ to protect against the disease, however, and that is what is needed at this time.

An executive order by President Trump, through use of his full emergency authority, could give Americans the same rights to HCQ for COVID which some of the poorest people in the world enjoy. Trump could even dispense HCQ at his rallies, which would both restore their massive numbers and help safeguard against spread of the virus.

But the medical establishment, such as Dr. John Fleming who is advising Trump’s Chief of Staff Mark Meadows, is impeding this solution to the crisis. As a physician, Dr. Fleming is instinctively trained to oppose OTC status for most medications, and he is beholden to the mindset of requiring people to see physicians first.

Americans are accustomed to being advised to consult a physician before starting a weight-loss plan, an attorney before writing a will, and an accountant before filing a tax return. In ideal situations, recommending use of a professional is non-controversial.

When there is a crisis, however, the dynamic is different. When thousands are dying unnecessarily, and millions are paralyzed by fear, directly alleviating that mortality and fear becomes paramount.

There is no valid reason to deny public access to low-dose HCQ, which studies show can protect against COVID, just as there is no legitimate reason to require a prescription for low-dose steroid cream (Cortisone) and many other over-the-counter medications. The political motivation to block access to HCQ justifies making it publicly available.

This is not a decision for Anthony Fauci or the medical establishment or FDA to make during a national crisis. This is for President Trump to decide, and make HCQ available quickly to the public.

If an intruder is discovered in one’s home in the middle of the night, no responsible father tries first to call an expert to get an opinion about what to do. Instead, quick and decisive action is taken, and that means OTC status for HCQ to conquer COVID.

Source: by John and Andy Schlafly, op-ed via Townhall.com, in ZeroHedge

BREAKING: Hydroxychloroquine Lowers SARS-CoV-2 Death Rate, New Study Finds

  • Twice as many patients survived when given hydroxychloroquine
  • No heart-related side effects reported
  • Early treatment appears to be key

The anti-malaria drug hydroxychloroquine helped lower the death rate in Covid-19 patients in the most recent study of the drug conducted by Henry Ford Health System.

Read more from Henry Ford Health System here.

Cardiologist Dr. William O’Neill, a medical director at the Henry Ford Health System in Detroit, Michigan, first spoke with “Full Measure” about the study while it was underway in May. The findings have just been published in the peer-reviewed International Journal of Infectious Diseases.

The large scale analysis examined 2,541 patients who had been hospitalized in six hospitals between March 10 and May 2, 2020.

More than twenty-six percent (26.4%) of patients who did not receive hydroxychloroquine died. Nearly seventy-four percent (73.6%) survived.

But among those who received hydroxychloroquine: 13% died and 87% survived.

One suggested concern flagged in previous studies of hydroxychloroquine did not materialize in the Henry Ford Health System Study: heart-related adverse events.

The positive results compared to some other studies of hydroxychoroquine could be attributed, in part, to the timing of treatment say the study’s scientists. Ninety-one percent (91%) of the patients in the study were given hydroxychloroquine within 48 hours of admission.

The study patients were at least 18 years old with a median age of 64. Fifty-six percent (56%) were African-American.

The study also found that patients who received the antibiotic azithromycin alone, or a combination of hydroxychloroquine and azithromycin, had a slightly better survival rate than those not treated with the drugs.

The analysis found 22.4% of those treated only with azithromycin died and 77.6% survived. Twenty point one percent (20.1%) treated with a combination of azithromycin and hydroxychloroquine died and 79.9% survived.

More than 26% (26.4%) of patients who were not treated with either medicine died and 73.6% survived. 

“Our analysis shows that using hydroxychloroquine helped save lives,” said neurosurgeon Dr. Steven Kalkanis, CEO, Henry Ford Medical Group and Senior Vice President and Chief Academic Officer of Henry Ford Health System. “As doctors and scientists, we look to the data for insight. And the data here is clear that there was benefit to using the drug as a treatment for sick, hospitalized patients.”

The study scientists point out that other reports on hydroxychloroquine that had less positive, mixed, or negative results were of different populations; administered hydroxychloroquine later during illness; used different doses, and/or the studies were not peer-reviewed.

The findings have been highly analyzed and peer-reviewed. We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring. Our dosing also differed from other studies not showing a benefit of the drug. And other studies are either not peer reviewed, have limited numbers of patients, different patient populations or other differences from our patients.” 

Dr. Marcus Zervos, co-author of study, division head of Infectious Disease for Henry Ford Health System

President Trump has garnered extensive criticism in the media for saying that if hydroxychloroquine proves to work in treating coronavirus, it could be a game changer.

Henry Ford Health System is also studying to see if hydroxychloroquine can prevent coronavirus. That study is titled: “Will Hydroxychloroquine Impede or Prevent COVID-19” or “WHIP COVID-19.” 

The study is enrolling 3,000 healthcare and frontline workers, but scientists say they are having trouble getting enough test volunteers due, in part, to the bad publicity surrounding hydroxychloroquine in the media; and because the government stepped in to limit use of the drug for coronavirus after criticism and safety concerns.

“Currently, the drug should be used only in hospitalized patients with appropriate monitoring, and as part of study protocols, in accordance with all relevant federal regulations,” says Dr. Marcus Zervos, co-author of study.

He adds that the possibility of a Covid-19 surge in the fall or sooner shows an urgency to identifying inexpensive and effective therapies and preventions.  Hyrdoxychloroquine can cost just pennies where other potential treatments, such as remdesivir, can cost thousands of dollars.

Click the link below to watch the Full Measure investigation about hydroxychloroquine:

http://fullmeasure.news/news/cover-story/hydroxychloroquine

Source: Sharyl Attkisson

***

Hydroxychloroquine: The One Chart You Need To See

 

Why Isn’t .GoV Embracing Hydroxychloroquine Protocol’s 90% Success Rate For Curing Chinese Flu Patients?

In a letter to Gov. Doug Ducey of Arizona, the Association of American Physicians and Surgeons (AAPS) presents a frequently updated table of studies that report results of treating COVID-19 with the anti-malaria drugs chloroquine (CQ) and hydroxychloroquine (HCQ, Plaquenil®).

To date, the total number of reported patients treated with HCQ, with or without zinc and the widely used antibiotic azithromycin, is 2,333, writes AAPS, in observational data from China, France, South Korea, Algeria, and the U.S. Of these, 2,137 or 91.6 percent improved clinically. There were 63 deaths, all but 11 in a single retrospective report from the Veterans Administration where the patients were severely ill.

The antiviral properties of these drugs have been studied since 2003. Particularly when combined with zinc, they hinder viral entry into cells and inhibit replication. They may also prevent overreaction by the immune system, which causes the cytokine storm responsible for much of the damage in severe cases, explains AAPS. HCQ is often very helpful in treating autoimmune diseases such as lupus and rheumatoid arthritis.

Additional benefits shown in some studies, AAPS states, is to decrease the number of days when a patient is contagious, reduce the need for ventilators, and shorten the time to clinical recovery.

Peer-reviewed studies published from January through April 20, 2020, provide clear and convincing evidence that HCQ may be beneficial in COVID-19, especially when used early, states AAPS. Unfortunately, although it is perfectly legal to prescribe drugs for new indications not on the label, the Food and Drug Administration (FDA) has recommended that CQ and HCQ should be used for COVID-19 only in hospitalized patients in the setting of a clinical study if available. Most states are making it difficult for physicians to prescribe or pharmacists to dispense these medications.

As the letter to Gov. Ducey notes, “Many nations, including Turkey and India, are protecting medical workers and contacts of infected persons prophylactically. According to worldometers.info, deaths per million persons from COVID-19 as of Apr 27 are 167 in the U.S., 33 in Turkey, and 0.6 in India.”

After Morocco and Algeria began using HCQ, a trend break and sharp reduction in their COVID-19 case fatality rateoccurred.

Vaccines and results of randomized double-blind controlled trials of new drugs are at best months away. But patients are dying now, while affordable, long-used drugs would be available except for government restrictions, AAPS states.

The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties in all states since 1943. The AAPS motto is omnia pro aegroto, meaning everything for the patient.

Source: AAPS

***

How to Cure Coronavirus With Hydroxychloroquine: an Exclusive Letter From Dr. Zelenko to Donald Trump

Predictive Monitoring of COVID-19

Hydroxychloroquine Cures CCP Virus

Investigative reporter Greg Hunger keeps yelling at the TV to give CCP sick people Hydroxychloroquine, every time he sees medical experts concentrating and pleading for masks, hospital beds and ventilators to combat the coronavirus.

Why not give Hydroxychloroquine? It has been proven in small tests around the world that it works with little to no side effects. In countries like China and Turkey, it is given at the first sign of trouble, and their results are clear— it works and actually removes the China virus.

Disclaimer of Liability:

Nothing Is Certain

There Are No Guarantees

You Are Solely Responsible For Your Decisions

New Drug Combo Wiped Out Coronavirus In Patients

  • A combination of two existing drugs is proving to be effective at eliminating the novel coronavirus in patients confirmed to have the infection. 
  • Treatment with both hydroxychloroquine, an anti-malaria drug, and the antibiotic azithromycin dramatically shortened the recovery time for people with COVID-19. 
  • More trials on a larger scale will be needed before we know just how effective this drug combo is. 

(BGR) A specific combination of existing drugs has shown it is capable of wiping out the novel coronavirus in a small-scale study conducted in France. Doctors gave confirmed COVID-19 patients a drug cocktail that included the anti-malaria drug hydroxychloroquine and the antibiotic azithromycin. The results of the trial were published in the International Journal of Antimicrobial Agents.

Remarkably, the anti-malaria medication proved to significantly reduce the duration of the infection in the patients who received it, but the combination of both drugs produced truly astounding results. In fact, by the fifth day of treatment, all of the patients who received the drug combo tested negative for the active virus.

The test is indeed promising, but it was so small in scale that it’s difficult to know how much stock to put in it. A much larger test would give us a more accurate idea of how effective these treatment options are, but it’s hard not to feel optimistic about it based on these results.

This is hardly the only drug trial to examine the effectiveness of existing medications on COVID-19 patients, and there have been several experimental treatments that show promise. A flu drug from Japan may be effective in treating patients, based on a report from China earlier this week, while other institutions are experimenting with the blood pressure drug losartan to see if it can prevent the virus from infecting patients in the first place.

What allowed the COVID-19 pandemic to cause such a disruption in our lives is that we know so little about it. No, it’s not the most deadly virus in the world, not by a long shot, but it’s extremely contagious and spreads rapidly through a population. Finding drugs that work to combat that spread is vital, and it’s only natural that we try existing options first while other drugs built specifically for this illness are in development.

Source: by Mike Wehner | BGR